Johnson & Johnson recently announced promising Phase 3 results for icotrokinra, a new investigational treatment for psoriasis, while facing legal challenges from a jury awarding a $3 million verdict linked to baby powder use. These developments coincided with a 3.77% rise in the company's stock over the past month. This price movement reflects broader market trends, as the Dow Jones was relatively flat amid ongoing U.S.-China tariff discussions. Johnson & Johnson's positive earnings report and dividend increase likely added weight to the company's price gains, aligning with overall market stability. Buy, Hold or Sell Johnson & Johnson? View our complete analysis and fair value estimate and you decide.NYSE:JNJ Revenue & Expenses Breakdown as at May 2025 Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent announcement of Johnson & Johnson's promising Phase 3 results for its investigational psoriasis treatment, icotrokinra, offers potential growth opportunities in its Innovative Medicine sector. This could positively influence revenue and earnings forecasts, potentially offsetting challenges such as the loss of exclusivity for STELARA. The company's previous strategic investments and expansion initiatives, especially in MedTech, aim to buffer these headwinds, leveraging their substantial investment in the U.S. to foster operational efficiency. Over the past five years, Johnson & Johnson's total shareholder return, including share price and dividends, was 21.32%. This contrasts its performance against the past year's underperformance, where the company lagged behind the US market's 8.2% growth while exceeding the Pharmaceuticals industry's negative 8.8% return. Analysts' consensus price target of US$169.98 reflects a 9.1% potential upside from the current share price, suggesting room for growth, assuming revenue and earnings projections materialize. Recent litigation outcomes, like the $3 million verdict associated with baby powder, continue to pose financial risks but have thus far been outweighed by positive developments and earnings support. In light of our recent valuation report, it seems possible that Johnson & Johnson is trading behind its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NYSE:JNJ. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Johnson & Johnson (NYSE:JNJ) Announces Positive Trial Results Amid Legal Setback
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...